Merck says some patents for its top-selling cancer drug, Keytruda, may be extended through 2029.

Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this ...

Armed with what CEO Robert Davis called the “broadest and widest pipeline we’ve had in years,” Merck is preparing for its ...

Merck (MRK) ’s stock surged by 41% in the last six months, driven not only by a modest revenue increase but also by a ...

By Atharva Singh and Arasu Kannagi Basil Feb 5 (Reuters) - Drug developer Eikon Therapeutics, headed by Merck veteran Roger ...

Global pharmaceutical company Merck (NYSE:MRK) will be reporting results this Tuesday before the bell. Here’s what you need ...

Merck recorded higher revenue in its fourth quarter, but expects earnings growth to slow as it ramps up acquisitions.

In its 2025 full year and fourth-quarter earnings call, Merck executives touted the merits of recent deals and what CEO ...

Q4 2025 earnings call highlights: 2026 guidance, KEYTRUDA LOE risks, $70B pipeline outlook, and new launches—read now.

A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin cancer after five years, new data confirming its prolonged benefit show.

For full-year 2025, Merck reported worldwide sales of $65B, up 1% Y/Y, or 2% excluding FX, while adjusted EPS totaled $8.98. Analysts had projected EPS of $8.94 for 2025 on revenue of $64.78B.

By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized vaccine continued to cut the risk of death or recurrence of the most deadly ...